Participated · Equity · Jun 2026

Beren Therapeutics P.B.C. is a founder-led biotech focused on discovery, development, and commercialization of cyclodextrin-based therapies that address defective intracellular cholesterol trafficking. Its lead program, adrabetadex, is under Priority Review by the U.S. FDA with a PDUFA target action date of November 17, 2026, and has been studied in clinical trials and expanded access programs since 2021. The company has built patient access and family support initiatives and intends to prepare for a potential U.S. commercial launch if adrabetadex is approved. Beren describes itself as a public benefit company that integrates patient, caregiver, clinician, and health-system needs into development and access planning. The recent $300 million financing package is intended to support commercial readiness and long-term care infrastructure and aims to position the company to be financially self-sustaining through potential commercialization. Beren is headquartered in Thousand Oaks, California.

Participated · Seed · May 2026

Reprogram Biosciences develops mRNA-encoded gene-combination therapeutics intended to reprogram tumor cells in situ to induce antigen-presenting function and activate antitumor immunity. The company uses an AI discovery engine, CellRecodeX, which integrates biological foundation models to identify and prioritize therapeutic reprogramming candidates and support pipeline expansion. Reprogram is focused on treating solid tumors with high unmet need and is operating at the preclinical stage. The team reports accelerated progress—advancing from concept to in vivo data within six months. Current plans funded by the seed round include advancing the lead program, expanding CellRecodeX, and supporting CMC activities. Founded in 2025, the company is based in San Carlos, California and has raised a total of $6 million to date.

Participated · Series D · Apr 2026

True Anomaly develops and delivers capabilities for space missions, including autonomous spacecraft, advanced payloads, mission software, and space-based interceptors. The company says its products enable the U.S. and its allies to secure the space environment and counter threats. Founded in 2022 and based in Centennial, CO, True Anomaly has offices in Colorado Springs, Washington, D.C., and Long Beach, CA, and is led by CEO Even Rogers. Financially, the company has now raised a total of $1 billion in capital, including a $650M Series D that closed with $50M of debt. In the next 18 months True Anomaly plans multiple missions in LEO and GEO and will conduct the VICTUS HAZE Tactically Responsive Space demonstration while advancing its payload portfolio. The company intends to use the new funding to accelerate delivery across its product portfolio and mission capabilities.

Participated · Series E · Apr 2026

Chapter offers an AI-native platform that powers licensed advisors to deliver personalized, impartial Medicare plan recommendations and help seniors maximize benefits. The company reviews every Medicare plan nationwide and has deployed products such as the most accurate provider directory and a prescription cost calculator for Medicare. Chapter reported rapid commercial traction in 2025, growing revenue threefold and surpassing $100 million in annual recurring revenue while maintaining flat corporate headcount. It is expanding its product set to launch additional financial products and to help members save across more of their spending. The business positions itself as the leading Medicare navigation option nationwide and partners with organizations to assist seniors with retirement healthcare decisions.

Participated · Series A · Jan 2026

Founded in 2024, Valinor Enterprises operates as an operational holding company that builds and acquires specialized “Product Companies” for the defense and broader public-sector markets. The firm centralizes infrastructure and go-to-market functions while decentralizing engineering, enabling it to move from demand signal to fielded product with unusual speed. In its first year Valinor publicly launched five companies—Harbor, Reflex, Dispatch, Streamline and Condor—that are already winning contracts across the Department of War, the Intelligence Community, civilian agencies and commercial customers. Management is now incubating new product lines in military construction, munitions lifecycle management and maritime support, with initial roll-outs slated for early 2026. The $54 million Series A financing announced in January 2026 lifts total capital raised to more than $85 million, providing resources to scale existing offerings, create additional product companies and pursue corporate development opportunities. No operating metrics such as revenue or headcount were disclosed in the announcement.